Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion; APLS Shares Surge 140%
Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals in a landmark deal valued at approximately $5.6 billion. Following the announcement, shares of Apellis Pharmaceuticals (APLS) skyrocketed by 140% in pre-market trading as investors reacted to the premium valuation. This strategic…
Read the full story